In an interview with PharmaShots, Paula Ragan, Ph.D., CEO, and President at X4 Pharmaceuticals shared her views on the data of Mavorixafor which showed increased immune cell levels regardless of patients having a CXCR4 mutation to treat multiple immunodeficiencies, presented at ASH 2021
Shots:
The ongoing long-term extension arm of the P-II trial evaluates Mavorixafor (CXCR4 antagonist) in patients with WHIM syndrome. The therapy continues…
